Scholarlink

Background <p>Steroidogenesis inhibitors are widely used in the treatment of persistent or recurrent Cushing disease (CD). A few patients who unexpectedly developed adrenal insufficiency (AI) after discontinuation of prolonged osilodrostat therapy were recently described for the first time.</p> Case presentation <p>We report three additional patients with CD who experienced unplanned discontinuation of steroidogenesis inhibitors due to symptoms of AI. All three patients developed symptomatic AI shortly after initiating medical therapy and therefore stopped treatment. Despite drug withdrawal, patients subsequently achieved and maintained biochemical remission, ongoing and observed at the last follow-up visit up to 38 months after drug interruption. </p> Conclusion <p>Long-term remission after interruption of steroidogenesis inhibitors may occur in selected patients with CD. Our cases contribute to the growing literature on potential long-lasting adrenal effects of therapy by providing longer-term follow-up and including metyrapone among the agents involved. These observations support hypotheses of sustained adrenal effects beyond transient enzyme inhibition and underscore the need for prospective studies to identify predictors and mechanisms underlying this unexpected outcome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Persistent remission after steroidogenesis inhibitor discontinuation in Cushing disease: a case series

  • 期刊论文

  • 发表日期：

    2026年4月1日

查看全文
  • Alessandra Mangone,
  • Elisa Sala,
  • Giulia Carosi,
  • Giulia Del Sindaco,
  • Roberta Mungari,
  • Arianna Cremaschi,
  • Iulia Petria,
  • Giacomo Noschese,
  • Veronica Lotito,
  • Giovanna Mantovani,
  • Emanuele Ferrante

摘要

Background

Steroidogenesis inhibitors are widely used in the treatment of persistent or recurrent Cushing disease (CD). A few patients who unexpectedly developed adrenal insufficiency (AI) after discontinuation of prolonged osilodrostat therapy were recently described for the first time.

Case presentation

We report three additional patients with CD who experienced unplanned discontinuation of steroidogenesis inhibitors due to symptoms of AI. All three patients developed symptomatic AI shortly after initiating medical therapy and therefore stopped treatment. Despite drug withdrawal, patients subsequently achieved and maintained biochemical remission, ongoing and observed at the last follow-up visit up to 38 months after drug interruption.

Conclusion

Long-term remission after interruption of steroidogenesis inhibitors may occur in selected patients with CD. Our cases contribute to the growing literature on potential long-lasting adrenal effects of therapy by providing longer-term follow-up and including metyrapone among the agents involved. These observations support hypotheses of sustained adrenal effects beyond transient enzyme inhibition and underscore the need for prospective studies to identify predictors and mechanisms underlying this unexpected outcome.